“Dermatological Drugs market set to grow to $34bn by 2022” says Visiongain report

14 August 2018
Pharma

Visiongain’ has launched a new pharma report Dermatological Drugs Market Forecast : Psoriasis, Skin Infection, Acne, Dermatitis, Others

The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth.

The lead analyst of the report commented "Visiongain notes that strong growth is expected in the skin structure infections (SSSI) sector of the dermatological drugs market. The increasing number of immunocompromised patients and the ageing population will contribute to the expansion expected in the segment of the market. We also expect growth to be driven by the development of new antibacterial drugs with better safety and efficacy profiles than existing antibiotics."

Leading companies featured in the report include AbbVie, Amgen, Bayer AG, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK), Johnson & Johnson, LEO Pharma, Merck & Co, Inc., Novartis, Pfizer

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

Read

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever